NASDAQ:BEAM Beam Therapeutics (BEAM) Stock Price, News & Analysis $24.12 +0.13 (+0.54%) Closing price 04:00 PM EasternExtended Trading$24.15 +0.03 (+0.12%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Beam Therapeutics Stock (NASDAQ:BEAM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Beam Therapeutics alerts:Sign Up Key Stats Today's Range$23.99▼$24.9350-Day Range$23.99▼$37.9252-Week Range$20.23▼$38.26Volume1.46 million shsAverage Volume2.07 million shsMarket Capitalization$2.49 billionP/E RatioN/ADividend YieldN/APrice Target$49.00Consensus RatingModerate Buy Company Overview Beam Therapeutics Inc. is a biotechnology company focused on developing genetic medicines using its proprietary base-editing technology. Unlike conventional gene-editing approaches that can make double-strand breaks in DNA, base editing is designed to make targeted changes to individual DNA letters, with the goal of treating diseases at their genetic source. The company is developing both ex vivo and in vivo therapies. Its pipeline has included programs for sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, glycogen storage disease type Ia and certain cancers. Beam’s work combines base-editing systems with delivery technologies intended to transport editors to specific cells or tissues. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam was co-founded by scientists including David R. Liu and J. Keith Joung. The company conducts research and clinical development aimed at serving patients internationally and has entered collaborations and partnerships to advance its gene-editing platform and therapeutic programs.AI Generated. May Contain Errors. Read More Beam Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreBEAM MarketRank™: Beam Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 588th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingBeam Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBeam Therapeutics has a consensus price target of $49.00, representing about 102.4% upside from its current price of $24.21.Amount of Analyst CoverageBeam Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Beam Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Beam Therapeutics are expected to decrease in the coming year, from ($4.49) to ($5.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -28.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -28.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Beam Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.97% of the float of Beam Therapeutics has been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 14.84, which indicates bearish sentiment.Change versus previous monthShort interest in Beam Therapeutics has recently increased by 5.86%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.50 News SentimentBeam Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Beam Therapeutics this week, compared to 6 articles on an average week.Search Interest14 people have searched for BEAM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows8 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,468,500.00 in company stock.Percentage Held by Insiders3.80% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Beam Therapeutics' insider trading history. Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BEAM Stock News HeadlinesThese 10 Stocks Are Squeeze Candidates Waiting to Happen2 hours ago | benzinga.comBeam Therapeutics (NASDAQ:BEAM) Cut to Strong Sell at Wall Street ZenSeptember 13 at 1:06 AM | americanbankingnews.comJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2 trillion, with Anthropic and OpenAI preparing IPOs of their own. But Najarian's top pick isn't an IPO. It's a small American company with a $6 billion market cap powering Elon Musk's newest venture, dubbed the Infinite Power Grid. The full story is laid out in his newly released presentation.September 14 at 1:00 AM | Banyan Hill Publishing (Ad)Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My ViewSeptember 11 at 7:14 PM | seekingalpha.comWedbush Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)September 11 at 9:12 AM | theglobeandmail.comWedbush Reiterates "Outperform" Rating for Beam Therapeutics (NASDAQ:BEAM)September 11 at 2:52 AM | americanbankingnews.comBeam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 11 at 2:14 AM | americanbankingnews.comBeam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit?September 10, 2026 | insidermonkey.comSee More Headlines BEAM Stock Analysis - Frequently Asked Questions How have BEAM shares performed this year? Beam Therapeutics' stock was trading at $27.72 at the start of the year. Since then, BEAM stock has decreased by 12.7% and is now trading at $24.21. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) released its quarterly earnings results on Tuesday, August, 4th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.11) by $0.07. The firm's revenue was down 94.2% on a year-over-year basis. Does Beam Therapeutics have any subsidiaries? The following companies are subsidiaries of Beam Therapeutics: Blink Therapeutics Inc.. When did Beam Therapeutics IPO? Beam Therapeutics (BEAM) raised $169 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 10,588,236 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Beam Therapeutics' major shareholders? Beam Therapeutics' top institutional investors include BlackRock Inc. (8.71%), ARCH Venture Management LLC (4.40%), California State Teachers Retirement System (3.47%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.50%). Insiders that own company stock include John M Evans, Fmr Llc, Giuseppe Ciaramella, Christine Bellon, Amy Simon, Terry-Ann Burrell and Bethany J Cavanagh. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Beam Therapeutics investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW), McKesson (MCK) and Yum! Brands (YUM). Company Calendar Last Earnings8/04/2026Today9/14/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 4 days ago, BEAM's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BEAM CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees540Year Founded2017Price Target and Rating Average Price Target for Beam Therapeutics$49.00 High Price Target$80.00 Low Price Target$26.00 Potential Upside/Downside+103.2%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.99 million Net Margins-54.75% Pretax Margin-55.45% Return on Equity-30.71% Return on Assets-24.07% Debt Debt-to-Equity Ratio0.09 Current Ratio14.57 Quick Ratio14.57 Sales & Book Value Annual Sales$139.74 million Price / Sales17.83 Cash FlowN/A Price / Cash FlowN/A Book Value$12.20 per share Price / Book1.98Miscellaneous Outstanding Shares103,290,000Free Float99,363,000Market Cap$2.49 billion OptionableOptionable Beta2.22 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:BEAM) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredWhat is Elon Building in Texas?Elon Musk's latest Texas project is massive - three times the size of Central Park and backed by a reported 12...InvestorPlace | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
